The Richest Woman in the World: How Gina Rinehart Earns her Billions
Why Dell Will Never Be Great Again
The powerful shareholder advisory firm, Institutional Shareholder Services (ISS), indicated that shareholders should reject the $1.25 billion buyout of Genesis HealthCare Corp. (NASDAQ: GHCI). The buyers include private equity firms Formation Capital LLC and JER Partners.Apparently ISS thinks that other bidders didn't have a chance to make a play for the company. In other words, Genesis shareholders may be leaving money on the table.
Genesis, of course, begs to differ. In fact, the company wrote a letter to shareholders saying that the deal is "compelling" and is valued at "all-time" highs for financial multiples for Genesis. Besides, the deal is getting close to completion and there could be a drop in the stock price if things don't go through.
Investors, however, don't seem to agree. The stock price for Genesis is currently at $63.26, above the buyout price of $63. In other words, meaning they think the price will get bumped up.
Tom Taulli is the author of various books, including the Complete M&A Handbook and the EDGAR-Online Guide to Decoding Financial Statements.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
